FUSION PHARMACEUTICALS INC (FUSN)
CA36118A1003 - Common Stock
We assign a fundamental rating of 3 out of 10 to FUSN. FUSN was compared to 588 industry peers in the Biotechnology industry. While FUSN seems to be doing ok healthwise, there are quite some concerns on its profitability. FUSN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year FUSN has reported negative net income.
In the past year FUSN has reported a negative cash flow from operations.
In the past 5 years FUSN always reported negative net income.
FUSN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
FUSN's Return On Assets of -33.20% is fine compared to the rest of the industry. FUSN outperforms 68.77% of its industry peers.
Looking at the Return On Equity, with a value of -42.66%, FUSN is in the better half of the industry, outperforming 73.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.2% | ||
| ROE | -42.66% | ||
| ROIC | N/A |
ROA(3y)-35.1%
ROA(5y)-30.86%
ROE(3y)-43.89%
ROE(5y)-40.25%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
FUSN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
FUSN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, FUSN has more shares outstanding
The number of shares outstanding for FUSN has been increased compared to 5 years ago.
The debt/assets ratio for FUSN has been reduced compared to a year ago.
2.2 Solvency
FUSN has an Altman-Z score of 15.23. This indicates that FUSN is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of FUSN (15.23) is better than 90.10% of its industry peers.
FUSN has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
FUSN has a Debt to Equity ratio of 0.16. This is in the lower half of the industry: FUSN underperforms 66.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 15.23 |
ROIC/WACCN/A
WACC8.13%
2.3 Liquidity
FUSN has a Current Ratio of 15.01. This indicates that FUSN is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of FUSN (15.01) is better than 90.44% of its industry peers.
A Quick Ratio of 15.01 indicates that FUSN has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 15.01, FUSN belongs to the best of the industry, outperforming 90.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 15.01 | ||
| Quick Ratio | 15.01 |
3. Growth
3.1 Past
FUSN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.50%, which is quite impressive.
FUSN shows a strong growth in Revenue. In the last year, the Revenue has grown by 40.82%.
EPS 1Y (TTM)26.5%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q29.09%
Revenue 1Y (TTM)40.82%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q-100%
3.2 Future
FUSN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.89% yearly.
The Revenue is expected to grow by 86.49% on average over the next years. This is a very strong growth
EPS Next Y1.08%
EPS Next 2Y-8.33%
EPS Next 3Y-9.3%
EPS Next 5Y4.89%
Revenue Next Year-76.64%
Revenue Next 2Y-48.87%
Revenue Next 3Y58.69%
Revenue Next 5Y86.49%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for FUSN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FUSN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as FUSN's earnings are expected to decrease with -9.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.33%
EPS Next 3Y-9.3%
5. Dividend
5.1 Amount
FUSN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FUSION PHARMACEUTICALS INC
NASDAQ:FUSN (5/3/2024, 7:00:01 PM)
After market: 21.44 -0.01 (-0.05%)21.45
-0.04 (-0.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.82B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -33.2% | ||
| ROE | -42.66% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 15.01 | ||
| Quick Ratio | 15.01 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)26.5%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y1.08%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)40.82%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y